title: Naturally occurring anti-interferon-alpha 2a antibodies in patients with acute viral hepatitis.
abstract: The occurrence of antibodies against recombinant human interferon-alpha 2a (IFN-alpha 2a) in patients with acute viral hepatitis (AVH) was examined by ELISA. Naturally occurring IgG anti-IFN-alpha 2a were found in 50% of patients with type A, 50% of those with type B and in 8.3% of those with non-A, non-B AVH. The corresponding frequencies of IgM antibodies were 80%, 30% and 33.3%, respectively. IgM anti-IFN-alpha 2a were found more frequently in patients with AVH type A than in normal control subjects (P less than 0.01). Anti-IFN-alpha 2a were detectable at the highest frequency 3 weeks after acute onset and then became negative. An absorption experiment revealed that IgM anti-IFN-alpha 2a did not cross-react with recombinant human IFN-alpha 2b. Immunoblotting analysis confirmed the binding of antibodies to IFN-alpha 2a. Sera positive for IgG and/or IgM anti-IFN-alpha 2a were unable to neutralize IFN-alpha 2a. The appearance of anti-IFN-alpha 2a was not correlated with disease severity. There was no evidence to suggest that anti-IFN-alpha 2a impaired the elimination of hepatitis virus. This is the first study to demonstrate the occurrence of anti-IFN-alpha 2a in patients with AVH. Detection of anti-IFN-alpha 2a may be useful for clarifying any underlying immune events in various diseases.
authors.affiliation: First Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Ikeda
authors.forename: G
authors.initials: G
authors.lastname: Toda
authors.forename: N
authors.initials: N
authors.lastname: Hashimoto
authors.forename: N
authors.initials: N
authors.lastname: Umeda
authors.forename: K
authors.initials: K
authors.lastname: Miyake
authors.forename: M
authors.initials: M
authors.lastname: Yamanaka
authors.forename: K
authors.initials: K
authors.lastname: Kurokowa
mesh_terms: D000208:Acute Disease; D001323:Autoantibodies / Q000032:analysis*; D003429:Cross Reactions / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D006506:Hepatitis A / Q000276:immunology*; D006509:Hepatitis B / Q000276:immunology*; D006526:Hepatitis C / Q000276:immunology*; D006801:Humans; D015151:Immunoblotting; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000276:immunology*; D011994:Recombinant Proteins
chemical_list: D001323:Autoantibodies; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins